非危重症住院患者高血糖的药物治疗
Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients.
作者信息
Mendez Carlos E, Umpierrez Guillermo E
出版信息
Diabetes Spectr. 2014 Aug;27(3):180-8. doi: 10.2337/diaspect.27.3.180.
Abstract
In Brief Hyperglycemia in the hospital setting affects 38-46% of noncritically ill hospitalized patients. Evidence from observational studies indicates that inpatient hyperglycemia, in patients with and without diabetes, is associated with increased risks of complications and mortality. Substantial evidence indicates that correction of hyperglycemia through insulin administration reduces hospital complications and mortality in critically ill patients, as well as in general medicine and surgery patients. This article provides a review of the evidence on the different therapies available for hyperglycemia management in noncritically ill hospitalized patients.
摘要
简而言之，医院环境中的高血糖影响38%-46%的非危重症住院患者。观察性研究的证据表明，无论有无糖尿病，住院患者的高血糖都与并发症和死亡风险增加相关。大量证据表明，通过胰岛素给药纠正高血糖可降低危重症患者以及普通内科和外科患者的医院并发症和死亡率。本文综述了非危重症住院患者高血糖管理可用的不同治疗方法的证据。
相似文献
1
Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients.非危重症住院患者高血糖的药物治疗
Diabetes Spectr. 2014 Aug;27(3):180-8. doi: 10.2337/diaspect.27.3.180.
2
Insulin Therapy in Hospitalized Patients.住院患者的胰岛素治疗。
Am J Ther. 2020 Jan/Feb;27(1):e71-e78. doi: 10.1097/MJT.0000000000001078.
3
Evidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients.住院非危重症患者高血糖的循证治疗
Curr Med Res Opin. 2022 Jan;38(1):43-53. doi: 10.1080/03007995.2021.1997288. Epub 2021 Nov 22.
4
Obstacles to optimal management of inpatient hyperglycemia in noncritically ill patients.非危重症患者住院高血糖优化管理的障碍
Hosp Pract (1995). 2012 Apr;40(2):36-43. doi: 10.3810/hp.2012.04.968.
5
Parenteral nutrition-associated hyperglycemia in non-critically ill inpatients increases the risk of in-hospital mortality (multicenter study).非危重症住院患者的肠外营养相关高血糖会增加住院期间的死亡率（多中心研究）。
Diabetes Care. 2013 May;36(5):1061-6. doi: 10.2337/dc12-1379. Epub 2012 Dec 6.
6
Use of insulin in the noncritically ill-hospitalized patients with hyperglycemia and diabetes.胰岛素在非危重症住院高血糖和糖尿病患者中的应用。
Crit Care Nurs Clin North Am. 2013 Mar;25(1):55-70. doi: 10.1016/j.ccell.2012.11.002.
7
THE MANAGEMENT OF HYPERGLYCEMIA IN NONCRITICALLY ILL HOSPITALIZED PATIENTS TREATED WITH CONTINUOUS ENTERAL OR PARENTERAL NUTRITION.非危重症住院患者在接受连续肠内或肠外营养治疗时的高血糖管理。
Endocr Pract. 2018 Oct 2;24(10):900-906. doi: 10.4158/EP-2018-0150. Epub 2018 Jul 23.
8
Hyperglycemia management using insulin in the acute care setting: therapies and strategies for care in the non-critically ill patient.在急性护理环境中使用胰岛素进行高血糖管理：非危重症患者的护理治疗和策略。
Ann Pharmacother. 2010 Jul-Aug;44(7-8):1222-30. doi: 10.1345/aph.1M695. Epub 2010 Jun 22.
9
Glycemic management in the inpatient setting.住院患者的血糖管理。
Hosp Pract (1995). 2012 Apr;40(2):44-55. doi: 10.3810/hp.2012.04.969.
10
A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline for the Management of Hyperglycemia in Adults Hospitalized for Noncritical Illness or Undergoing Elective Surgical Procedures.一项支持内分泌学会成人非危重症住院或择期手术患者高血糖管理临床实践指南的系统评价。
J Clin Endocrinol Metab. 2022 Jul 14;107(8):2139-2147. doi: 10.1210/clinem/dgac277.
引用本文的文献
1
A Real-World Study of Oral Antihyperglycemic Agents as Compared With Basal Insulin in Hospitalized Patients With Type 2 Diabetes.2型糖尿病住院患者口服降糖药与基础胰岛素对比的真实世界研究
Endocr Pract. 2025 Jul 8. doi: 10.1016/j.eprac.2025.06.014.
2
Blood glucose management in hospitalized patients: a review of current literature.住院患者的血糖管理：当前文献综述
Ann Med Surg (Lond). 2025 Feb 26;87(4):2020-2025. doi: 10.1097/MS9.0000000000002991. eCollection 2025 Apr.
3
Glucagon-Like Peptide-1 Receptor Agonist Use is Not Associated With Increased Complications After Total Knee Arthroplasty in Patients With Type-2 Diabetes.胰高血糖素样肽-1受体激动剂的使用与2型糖尿病患者全膝关节置换术后并发症增加无关。
Arthroplast Today. 2024 Oct 11;30:101506. doi: 10.1016/j.artd.2024.101506. eCollection 2024 Dec.
4
Medical education on hospital hyperglycemia improving knowledge and outcomes.医院高血糖症的医学教育提高了知识和结果。
Arch Endocrinol Metab. 2024 Feb 19;68:e230003. doi: 10.20945/2359-4292-2023-0003. eCollection 2024.
5
Plant-derived cell-penetrating microprotein α-astratide aM1 targets Akt signaling and alleviates insulin resistance.植物源细胞穿透微蛋白 α-astratide aM1 靶向 Akt 信号通路并缓解胰岛素抵抗。
Cell Mol Life Sci. 2023 Sep 16;80(10):293. doi: 10.1007/s00018-023-04937-y.
6
Prospective Nutraceutical Effects of Cinnamon Derivatives Against Insulin Resistance in Type II Diabetes Mellitus-Evidence From the Literature.肉桂衍生物对II型糖尿病胰岛素抵抗的前瞻性营养保健作用——来自文献的证据
Dose Response. 2023 Sep 10;21(3):15593258231200527. doi: 10.1177/15593258231200527. eCollection 2023 Jul-Sep.
7
Managing Patients Undergoing Orthopedic Surgery to Improve Glycemic Outcomes.管理接受骨科手术的患者以改善血糖结局。
Curr Diab Rep. 2022 Jan 6;21(12):68. doi: 10.1007/s11892-021-01434-z.
8
Synergistic effect of micronutrients and metformin in alleviating diabetic nephropathy and cardiovascular Dysfunctioning in diabetic rat.微量营养素与二甲双胍对减轻糖尿病大鼠糖尿病肾病及心血管功能障碍的协同作用。
J Diabetes Metab Disord. 2021 Apr 5;20(1):533-541. doi: 10.1007/s40200-021-00776-5. eCollection 2021 Jun.
9
Medical software applications for in-hospital insulin therapy: A systematic review.用于院内胰岛素治疗的医学软件应用：一项系统综述。
Digit Health. 2020 Dec 26;6:2055207620983120. doi: 10.1177/2055207620983120. eCollection 2020 Jan-Dec.
10
Optimizing diabetes mellitus care to improve COVID-19 outcomes in resource-limited settings in Africa.在非洲资源有限的环境中优化糖尿病护理以改善COVID-19治疗结果。
Ther Adv Infect Dis. 2021 Apr 26;8:20499361211009380. doi: 10.1177/20499361211009380. eCollection 2021 Jan-Dec.
本文引用的文献
1
Metformin-associated lactic acidosis.二甲双胍相关性乳酸酸中毒
Am J Med Sci. 2015 Mar;349(3):263-7. doi: 10.1097/MAJ.0b013e3182a562b7.
2
The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study.在危重症外科患者强化胰岛素治疗期间输注胰高血糖素样肽-1（7-36）酰胺的糖调节益处：一项初步研究。
Crit Care Med. 2014 Mar;42(3):638-45. doi: 10.1097/CCM.0000000000000035.
3
Increased glycemic variability is independently associated with length of stay and mortality in noncritically ill hospitalized patients.血糖变异性增加与非危重症住院患者的住院时间和死亡率独立相关。
Diabetes Care. 2013 Dec;36(12):4091-7. doi: 10.2337/dc12-2430. Epub 2013 Oct 29.
4
Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study.静脉注射胰高血糖素样肽-1（7-36）酰胺预防心脏手术期间高血糖：一项随机、双盲、安慰剂对照研究。
J Cardiothorac Vasc Anesth. 2014 Jun;28(3):618-25. doi: 10.1053/j.jvca.2013.06.021. Epub 2013 Oct 19.
5
K(ATP) channels and islet hormone secretion: new insights and controversies.K(ATP) 通道与胰岛激素分泌：新的认识与争议。
Nat Rev Endocrinol. 2013 Nov;9(11):660-9. doi: 10.1038/nrendo.2013.166. Epub 2013 Sep 17.
6
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂治疗 2 型糖尿病：系统评价和荟萃分析。
Ann Intern Med. 2013 Aug 20;159(4):262-74. doi: 10.7326/0003-4819-159-4-201308200-00007.
7
Glucose variability is an independent predictor of mortality in hospitalized patients treated with total parenteral nutrition.血糖变异性是接受全胃肠外营养治疗的住院患者死亡率的独立预测因素。
Endocr Pract. 2014 Jan;20(1):41-5. doi: 10.4158/EP13131.OR.
8
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.沙格列汀与 2 型糖尿病患者的心血管结局。
N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.
9
Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study.西他列汀治疗2型糖尿病普通内科和外科住院患者的安全性和有效性：一项前瞻性、随机、对照研究。
Diabetes Care. 2013 Nov;36(11):3430-5. doi: 10.2337/dc13-0277. Epub 2013 Jul 22.
10
Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment.基于肠促胰岛素的治疗是否已准备好用于住院 2 型糖尿病患者的治疗？：胰岛素治疗已被证明有效，被认为是治疗的主要手段。
Diabetes Care. 2013 Jul;36(7):2112-7. doi: 10.2337/dc12-2233.
Zotero 插件